GlyNAC Reversed Nine Aging Defects in Twenty-Four Older Adults. A 114-Person Trial Ran Two Weeks and Found Nothing.
Glutathione is the antioxidant the body makes for itself, and older adults make far less of it than young adults do. That much is settled. What makes glutathione unusual among longevity targets is that the deficiency has a known cause and a cheap fix: the body runs short on two amino acids needed to build the molecule, and supplying them restores production within about two weeks. A team at Baylor College of Medicine spent fifteen years testing what happens when you keep that correction running for months instead of weeks. Their trials report oxidative stress cut by roughly three quarters, inflammatory markers down by half or more, mitochondrial fat burning up 78 percent, and mice living 24 percent longer. Those trials enrolled eight people, then twenty-four. In 2022 a separate group ran the largest glutathione precursor trial to date in 114 healthy older adults and found no significant change in blood glutathione at all. Both results are in the literature, neither has been retracted, and the gap between them comes down almost entirely to dose and duration.
Key Takeaways: What the GlyNAC Evidence Actually Shows
Older adults have markedly lower red blood cell glutathione than young adults, and a 2011 study in the American Journal of Clinical Nutrition using labeled glycine infusions showed the cause is a reduced synthesis rate rather than faster consumption, with two weeks of cysteine and glycine supplementation fully restoring both synthesis and concentration. A 24-week open-label pilot published in Clinical and Translational Medicine in 2021 gave glycine at 1.33 mmol per kilogram per day and N-acetylcysteine at 0.81 mmol per kilogram per day to eight adults aged 71 to 80, reporting red cell glutathione up 200 percent, TBARS down 75 percent, IL-6 down 77 percent, TNF-alpha down 57 percent, HOMA-IR down 59 percent, 8-OHdG DNA damage down 66 percent, grip strength up 14.4 percent and Montreal Cognitive Assessment scores up 3.1 points. The only randomized placebo-controlled trial at that dose gave GlyNAC at 100 mg per kilogram per day of each compound to 24 older adults with a mean age of 71 for 16 weeks against an alanine placebo, published in The Journals of Gerontology Series A in 2023, and reported mitochondrial fatty acid oxidation up 78 percent, IL-6 down 78 percent, TBARS and F2-isoprostane both down 72 percent, HOMA-IR down 64 percent, grip strength improved at p equals 0.004 and systolic blood pressure reduced at p equals 0.043. In C57BL/6J mice started at 65 weeks of age, GlyNAC in the feed raised lifespan from 104.0 weeks to 128.6 weeks, a 24 percent increase at p below 0.0001, with nearly identical gains in males at 24.2 percent and females at 23.4 percent, published in Nutrients in 2022. A separate randomized trial published in Frontiers in Aging in 2022 gave 114 healthy older adults fixed doses of 2.4, 4.8 or 7.2 grams per day of combined glycine and N-acetylcysteine for 14 days and found no significant change in total blood glutathione at the highest dose, at p equals 0.278, with a significant 10.47 percent rise appearing only in a post-hoc subgroup that started with both high oxidative stress and low glutathione. Every Baylor trial that included a washout period found the gains receded once supplementation stopped, with red cell glutathione falling 67 percent across 12 weeks off the supplement. No GlyNAC trial has enrolled healthy middle-aged men as its study population, and no GlyNAC trial has measured a hard clinical endpoint such as fracture, hospitalization or mortality in humans.
What Is GlyNAC and Why These Two Amino Acids?
GlyNAC is simply glycine plus N-acetylcysteine taken together, and the pairing exists because those are the two ingredients the body runs short of when it builds glutathione. Glutathione is a tripeptide made from three amino acids: glutamate, cysteine and glycine. Glutamate is abundant. Cysteine and glycine are the ones that run low, and cysteine is the classic rate-limiting substrate because free cysteine is unstable in the bloodstream and the body keeps very little of it circulating. N-acetylcysteine solves that delivery problem, since the acetyl group protects the molecule until it is absorbed and then cleaved to release cysteine inside the cell. Glycine is the second constraint, and it is a real one despite glycine being classified as a nonessential amino acid, because typical adult diets supply less glycine than the body's collagen turnover and glutathione synthesis together demand. Giving one without the other tends to underperform, which is why the research protocols use both. This is not a peptide and not a drug. It is two amino acids sold separately in bulk at grocery-store prices, which is part of why the compound attracts attention and part of why no company has funded a large trial of it.
Why Does Glutathione Fall With Age?
Glutathione falls with age because the body synthesizes less of it, not because it burns through it faster or because the enzymes stop working. Sekhar and colleagues established this in the American Journal of Clinical Nutrition in 2011 using stable-isotope labeled glycine infused into eight elderly and eight younger participants, which allowed them to measure the actual rate at which red blood cells were manufacturing new glutathione rather than just the concentration sitting there. Older participants showed both lower concentrations and a markedly lower synthesis rate. Two weeks of dietary cysteine and glycine supplementation restored synthesis and concentration to young-adult levels and lowered plasma markers of oxidative stress and oxidant damage. That result matters more than the supplement question, because it identifies the bottleneck as substrate availability. A machine that has stopped working is a hard problem. A machine that is idling because nobody loaded it is a much easier one, and glutathione appears to be the second kind.
What Twenty-Four Weeks of GlyNAC Did to Eight Older Adults
Percent change from baseline in the open-label pilot published in Clinical and Translational Medicine in 2021, which gave glycine at 1.33 mmol per kilogram per day and N-acetylcysteine at 0.81 mmol per kilogram per day to eight adults aged 71 to 80 for 24 weeks. Red cell glutathione tripled. Oxidative stress, inflammation, DNA damage, insulin resistance and endothelial markers all fell substantially. The trial had eight participants, five of them women, and no control group, so these numbers describe what changed rather than what the supplement caused.
What Did the Twenty-Four-Week Pilot Actually Find?
It found large improvements across nearly every marker measured, in eight people, with no control group. The pilot published in Clinical and Translational Medicine in 2021 enrolled eight older adults aged 71 to 80, five women and three men, and gave them glycine at 1.33 mmol per kilogram per day and N-acetylcysteine at 0.81 mmol per kilogram per day for 24 weeks. Red blood cell glutathione rose roughly 200 percent. TBARS, a lipid peroxidation marker, fell 75 percent and F2-isoprostane fell 74 percent. Interleukin-6 fell 77 percent and TNF-alpha fell 57 percent. HOMA-IR, the standard index of insulin resistance, fell 59 percent. The endothelial adhesion molecule sVCAM1 fell 46 percent and the DNA oxidation marker 8-OHdG fell 66 percent. On the functional side, grip strength rose 14.4 percent, six-minute walk distance rose 10.3 percent, gait speed rose to young-adult levels, Montreal Cognitive Assessment scores gained 3.1 points, body fat fell about 4 percent and waist circumference dropped 4 centimeters. Eight participants and no placebo arm means this study cannot separate the supplement from time, attention, seasonal variation or the tendency of any measured value to drift toward the average on repeat testing. What it does establish is a hypothesis large enough to be worth testing properly.
Did the Randomized Placebo-Controlled Trial Confirm It?
Broadly yes, at a smaller magnitude and in a still-small sample. The randomized trial published in The Journals of Gerontology Series A in 2023 enrolled 24 older adults with a mean age of 71 and randomized them double-blind to GlyNAC at 100 mg per kilogram per day of each compound or to an isonitrogenous alanine placebo for 16 weeks, with 12 young adults taking GlyNAC for two weeks as a reference group. Mitochondrial fatty acid oxidation rose 78 percent and respiratory quotient fell 9 percent, which together indicate a shift toward burning fat rather than carbohydrate. TBARS and F2-isoprostane each fell 72 percent. Interleukin-6 fell 78 percent and TNF-alpha fell 54 percent. Fasting insulin fell 65 percent and HOMA-IR fell 64 percent. Grip strength in the dominant hand improved at p equals 0.004, the chair-rise test at p equals 0.002, waist circumference at p equals 0.002 and systolic blood pressure at p equals 0.043. No cognitive testing was performed in this trial. The alanine placebo is a thoughtful design choice because it matches the nitrogen load of the active supplement, which rules out the possibility that the results simply reflect eating more protein. The honest limitation is arithmetic: 24 participants split into two arms leaves twelve people per group, and effects of the size reported here would be worth confirming in a few hundred.
The Randomized Trial, Sixteen Weeks Against an Alanine Placebo
Percent change in 24 older adults with a mean age of 71 who took 100 mg per kilogram per day each of glycine and N-acetylcysteine for 16 weeks in a double-blind trial published in The Journals of Gerontology Series A in 2023. Mitochondrial fatty acid oxidation rose 78 percent. Interleukin-6 fell 78 percent, TBARS and F2-isoprostane both fell 72 percent, and HOMA-IR fell 64 percent. Grip strength improved at p equals 0.004, the chair-rise test at p equals 0.002, waist circumference at p equals 0.002 and systolic blood pressure at p equals 0.043. This is the only randomized placebo-controlled GlyNAC trial published at full dose.
Why Did a 114-Person Trial Find Nothing?
Because it used a fraction of the dose for a fraction of the time. Lizzo and colleagues published a randomized placebo-controlled trial in Frontiers in Aging in 2022 that enrolled 114 healthy older adults aged 60 to 85 and randomized them to fixed daily doses of 2.4, 4.8 or 7.2 grams of combined glycine and N-acetylcysteine, or placebo, for 14 days. The primary endpoint was total glutathione in whole blood. At the highest dose it read 959.6 mg per liter against 903.5 in placebo, at p equals 0.278. The ratio of free glutathione to its oxidized form did not move either, at p equals 0.739. A post-hoc subgroup restricted to participants who began with both above-median oxidative damage and below-median glutathione did show a 10.47 percent rise at p equals 0.016. Now compare the exposures. The Baylor protocols dose by body weight, so an 80 kilogram man takes about 8 grams of glycine and 8 grams of N-acetylcysteine daily, roughly 16 grams in total, and takes it for 16 to 24 weeks. The highest Lizzo arm delivered 7.2 grams daily for 14 days, which works out to about 101 grams over the study against roughly 1,792 grams in the 16-week Baylor trial. That is not a failed replication. It is a different experiment, and it is genuinely useful information for anyone taking a two-gram capsule and expecting the trial results.
The Positive and Negative Trials Were Not Testing the Same Thing
Total grams of glycine plus N-acetylcysteine delivered to each participant across the whole study, calculated for an 80 kilogram adult. The Baylor trials dosed by body weight at roughly 16 grams per day and ran for 16 to 24 weeks. The Lizzo trial published in Frontiers in Aging in 2022 randomized 114 healthy older adults to fixed daily amounts of 2.4, 4.8 or 7.2 grams for 14 days and found no significant change in total blood glutathione at its highest dose, at p equals 0.278. The highest Lizzo arm delivered about 6 percent of what the shorter Baylor trial delivered.
Does GlyNAC Extend Lifespan?
In mice, by 24 percent, starting in old age. The study published in Nutrients in 2022 took C57BL/6J mice at 65 weeks of age, the point at which this strain shows falling glutathione alongside mitochondrial dysfunction and rising oxidative stress, and gave half of them GlyNAC in the feed at 1.6 mg per gram each of glycine and N-acetylcysteine while the other half stayed on an isocaloric and isonitrogenous control diet. The GlyNAC group lived 128.6 weeks on average against 104.0 in controls, an increase of 24 percent at p below 0.0001, and the effect was almost identical in males at 24.2 percent and females at 23.4 percent. Total glutathione rose 156 to 193 percent across organs and reduced glutathione rose 174 to 301 percent. TBARS fell 43.7 to 52.2 percent. Expression of PGC1-alpha, PPAR-alpha and ATP5A improved, PINK1 rose in a pattern consistent with restored mitophagy, SirT3 rose, and the DNA damage marker phospho-H2AX fell in heart, liver and kidney. Starting the intervention late in life and still getting a lifespan effect is the feature that makes this result interesting rather than merely encouraging. It is also a mouse result, in one strain, from one laboratory, and no compound has ever been shown to extend human lifespan.
What Happens When You Stop Taking It?
The gains recede, and every Baylor trial that built in a washout found the same thing. In the 24-week pilot, participants stopped GlyNAC and were followed for another 12 weeks, over which red cell glutathione fell 67 percent, oxidative stress markers climbed again, and physical and cognitive scores dropped back toward baseline, with some inflammatory improvements lingering longer than the rest. The open-label trial in eight people living with HIV, published in 2020, gave glycine at 1.31 mmol per kilogram per day and N-acetylcysteine at 0.83 mmol per kilogram per day for 12 weeks and reported muscle glutathione up 340 percent, red cell glutathione up 46 percent, TBARS down 81 percent, insulin resistance down 69 percent, grip strength up 25 to 29 percent and Montreal Cognitive Assessment scores up 18 percent. Eight weeks after stopping, most of those measures had reverted toward where they started. Read plainly, this means GlyNAC behaves like nutritional replacement rather than like a repair. It corrects a deficiency for as long as it is supplied, and the underlying reason the body was not synthesizing enough glutathione on its own remains untouched. Anyone weighing this compound should treat it as an indefinite commitment or not bother, and should also recognize that no trial has run long enough to describe what indefinite gram-level dosing does over years.
Everything Came Back After the Supplement Stopped
A schematic reading of the washout periods built into the Baylor trials, with baseline indexed to 100. In the 24-week pilot, red cell glutathione roughly tripled during supplementation and then fell 67 percent across the following 12 weeks without it, returning close to where it started. Oxidative stress markers rose again and physical function scores dropped back. The 12-week HIV trial showed the same pattern across an eight-week washout. Values here are directional rather than exact reported percentages, so read the shape rather than the height.
- Red cell glutathione
- Oxidative stress markers
- Grip strength
What Doses Are Used in Research, and What Is Known About Safety?
Research protocols use 100 mg per kilogram per day of each compound, which is roughly 8 grams of glycine and 8 grams of N-acetylcysteine daily for an 80 kilogram adult, usually split across two doses with food. The published safety record at that exposure is unremarkable. The 16-week randomized trial reported the regimen was safe and well tolerated, and the longer pilot and HIV studies recorded no serious adverse events. The practical obstacles are volume and taste rather than toxicity, since 16 grams of powder daily is a substantial amount to swallow and N-acetylcysteine has a sulfurous smell that many people find difficult. Gastrointestinal upset is the most commonly reported complaint with high-dose N-acetylcysteine. Two further points belong here. N-acetylcysteine occupies an unusual regulatory position in the United States, because the FDA holds that it was approved as a drug before being marketed as a supplement and is therefore technically excluded from the dietary supplement definition, while issuing final guidance in August 2022 stating it will exercise enforcement discretion, with a rulemaking still pending as of late 2025. And for men who train, there is a live question about antioxidant timing: exercise-generated reactive oxygen species are part of the signal that drives mitochondrial and hypertrophic adaptation, and high-dose antioxidants taken around training sessions have been shown in several studies to blunt some of those adaptations. None of the GlyNAC trials studied trained men or controlled for supplement timing relative to exercise, so this remains an open question rather than a documented problem.
How Should a Man Read the GlyNAC Evidence Right Now?
The biochemistry is solid, the human trials are small and nearly all from one laboratory, and the effect requires continuous dosing to persist. Those three facts frame everything else. On the supportive side, the glutathione deficit of aging is a documented, mechanistically explained, correctable shortfall, which is a rarer thing in longevity research than it sounds. A late-life mouse study showed a 24 percent lifespan gain in both sexes. The randomized human trial used a well-chosen placebo and reported improvements in mitochondrial fuel oxidation, inflammatory markers and physical function that are internally consistent with the proposed mechanism. Against that, essentially the entire human evidence base comes from Sekhar's group at Baylor College of Medicine, the largest trial there enrolled 24 older adults, no independent group has reproduced the full-dose protocol, the one large independent trial that tested a lower dose for two weeks found nothing on its primary endpoint, and no study has measured whether any of this translates into fewer falls, fewer fractures, fewer hospital admissions or longer life in a person. Three things follow for a man in his forties or fifties. Every participant in every GlyNAC trial was either over 60 or living with HIV, so the population studied is not him. The dose that produced the published results is roughly ten times what a typical retail capsule delivers, and a two-gram-a-day habit is not the intervention these trials tested. And the washout data are unambiguous that stopping returns you to where you started, which makes this a question about a permanent daily routine rather than a course of treatment. The trial that would settle this, a properly powered multi-center study with functional endpoints, has not been run, and the low cost and unpatentable nature of two bulk amino acids is a fair part of the reason why.
The GlyNAC Record on One Axis
Every strand of the GlyNAC evidence arranged as a single schematic map. Violet marks what the published data support, amber marks findings that are real but narrower than they sound, and grey marks claims the evidence does not carry. The biochemistry is well established and the mouse lifespan result is striking. The human trials are small, nearly all from one laboratory at Baylor College of Medicine, and every one of them showed the gains disappearing once the supplement stopped.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.